
Supplementary Materials:

Supplementary Figure 1: Study Design and Inclusion/Exclusion Criteria



Inclusion Criteria:

PDC=Proportion of days covered


- (i) Age ≥ 18 Years,
- (ii) MS diagnosed patients with Index DMA Prescription, and
- (iii) Continuous Eligibility during baseline 6 and follow-up 12 months

Exclusion Criteria:


- (i) Combination medication users, and
- (ii) Teriflunomide users

Supplementary Figure 2: Adherence Trajectories with 4 and 5 groups, and for oral and injectable DMA users separately

a) Four Groups




b) Five Groups




Adherence Trajectories

C. Trajectories for Oral and Injectable DMA Users Separately



Supplementary Figure 3: Standardized Differences between Covariates of Oral Fingolimod and Injectable DMA Users Before and After IPTW Matching



Standardized differences before and after IPTW Threshold: -0.25 to 0.25

Abbreviations: MS – Multiple Sclerosis, DMA – Disease Modifying Agent, IPTW - inverse probability treatment weights